Updated Experience with Inolimomab as Treatment for Corticosteroid-Refractory Acute Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 435-439

  García Cadenas, Irene ^a   Valcárcel, David ^a   Martino, Rodrigo ^a   Piñana, Jose Luis ^a,b   Novelli, Silvana ^a   Esquirol, Albert ^a   Garrido, Ana ^a   Moreno, Maria Estela ^a   Granell, Miquel ^a   Moreno, Carol ^a   Saavedra, Silvana ^a   Briones, Javier ^a   Brunet, Salut ^a   Sierra, Jorge ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE MANISES   (Spain)

Author keywords

Acute graft versus host disease; Allogeneic stem cell transplantation; Anti interleukin 2R; Inolimomab; Steroid refractory

Indexed keywords

INOLIMOMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANDIDEMIA; CAUSE OF DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TRACT; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE ASPERGILLOSIS; LONG TERM SURVIVAL; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PREDICTION; RASH; RETROSPECTIVE STUDY; STAPHYLOCOCCAL BACTEREMIA; SYSTEMIC MYCOSIS;

ACUTE DISEASE; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84873716183     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.11.012     Document Type: Article

References (17)

1. Weisford D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
2. Xhaard A., Rocha V., Bueno B., et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012, 18:406-413.
3. Martin P., Rizzo J.D., Wingard J.R., et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012, 18:1150-1163.
4. Pidala J., Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:1504-1518.
5. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
6. BMT CTN Protocol 0802. A multi-center, randomized, double blind, phase III trial evaluating corticosteroids with mycophenolate mofetil vs. corticosteroids with placebo as initial systemic treatment of acute GVHD. Blood and Marrow Transplant Clinical Trials Network. Request for Proposal RFP C10-0047.
7. Martin P., Inamoto Y., Flowers M.E., Carpenter P.A. Secondary treatment of acute graft versus host disease: a critical review. Biol Blood Marrow Transplant 2012, 18:982-988.
8. Saliba R.M., Couriel D.R., Giralt S., et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 2012, 47:125-131.
9. Levine J.E., Logan B., Wu J., et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010, 16:1693-1699.
10. Bay J., Dhédin N., Goerner M., et al. Inolimomab in steroid-refractory acute graft versus host disease following allogeneic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005, 80:782-788.
11. Schub N., Günther A., Schrauder A., et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011, 46:143-147.
12. Busca A., Locatelli F., Marmont F., et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:45-52.
13. Piñana J.L., Valcárcel D., Martino R., et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006, 12:1135-1141. [Erratum in: Biol Blood Marrow Transplant 2007;13:124.].
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
15. Piñana J.L., Martino R., Barba P., et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010, 45:534-542.
16. Hsu B., May R., Carrum G., et al. Use of antithymocite globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001, 28:945-950.
17. Hervé P., Wijdenes J., Bergerat J.P., et al. Treatment of refractory acute graft versus host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990, 75:1017-1023.